アブストラクト
| Title | 進行膵癌の化学療法 |
|---|---|
| Subtitle | 特集 進行胆道癌・膵癌の治療限界を打ち破る - 症例から学ぶ究極の治療 - |
| Authors | 岡野尚弘1), 西岡真理子1), 杉浦ちとせ1), 前園知宏1), 河合桐男1), 小林敬明1), 水谷友紀1), 長島文夫1), 古瀬純司1) |
| Authors (kana) | |
| Organization | 1)杏林大学医学部腫瘍内科学 |
| Journal | 胆と膵 |
| Volume | 41 |
| Number | 5 |
| Page | 487-492 |
| Year/Month | 2020 / 5 |
| Article | 報告 |
| Publisher | 医学図書出版 |
| Abstract | 「要約」: 化学療法のみで根治や長期生存が得られる進行膵癌患者は極めて少ない. FOLFIRI-NOX療法とゲムシタビン+ナブパクリタキセル療法の登場により, 切除不能から切除可能となり, conversion surgeryによって長期生存が得られるという報告がされてきている. このように, 化学療法に手術を組み合わせた集学的治療こそが進行膵癌に対する最善の治療戦略となりうるものであり, 内科医, 外科医の密な連携が必要となっている. 膵癌におけるprecision medicineの開発も進んでおり, 生殖細胞系列のBRCA遺伝子変異に対するプラチナ製剤, PARP阻害薬の有効性が確認され, 本邦でも承認にむけた取り組みが進められている. また, マイクロサテライト不安定性-high固形癌に対するペムブロリズマブ, 神経栄養因子受容体チロシンキナーゼ(NTRK)融合遺伝子を有する固形癌に対するエヌトレクチニブが保険承認され, 頻度は極めて低いが適応となる膵癌患者がいるため, 患者をどのように同定し最適な時期に最適な治療を届けるかが重要となっている. |
| Practice | 臨床医学：内科系 |
| Keywords | pancreatic cancer, conversion surgery, germline BRCA, platinum-based chemotherapy |
- 全文ダウンロード： 従量制、基本料金制の方共に1,023円(税込) です。
参考文献
- 1) Conroy T, Desseigne F, Ychou M, et al.:FOLFIRI-NOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825,2011.
- 2) Von Hoff DD, Ervin T, Arena FP, et al.:Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691-1703,2013.
- 3) Okusaka T, Ikeda M, Fukutomi A, et al.:Phase II study of FOLFIRINOX for chemotherapy-naive Jap-anese patients with metastatic pancreatic cancer. Cancer Sci 105:1321-1326,2014.
- 4) Ueno H, Ikeda M, Ueno M, et al.:Phase I/II study of nab-paclitaxel plus gemcitabine for chemother-apy-naive Japanese patients with metastatic pancre-atic cancer. Cancer Chemother Pharmacol 77:595-603,2016.
- 5) Ozaka M, Ishii H, Sato T, et al.: A phase II study of modified FOLFIRINOX for chemotherapy-naive patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 81:1017-1023,2018.
残りの15件を表示する
- 6) Wang-Gillam A, Li CP, Bodoky G, et al.:Nanoliposo-mal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gem-citabine-based therapy(NAPOLI-1): a global, ran-domised, open-label, phase 3 trial. Lancet 387:545-557,2016.
- 7) O'Reilly EM, Lee JW, Zalupski M, et al.:Randomized, multicenter, phase II trial of gemcitabine and cispla-tin with or without veliparib in patients with pan-creas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol 2020[Epub ahead of print].
- 8) Golan T, Hammel P, Reni M, et al.:Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 381:317-327,2019.
- 9) Suker M, Beumer BR, Sadot E, et al.:FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 17:801-810,2016.
- 10) Nitsche U, Wenzel P, Siveke JT, et al.:Resectability after first-line FOLFIRINOX in initially unresectable locally advanced pancreatic cancer: a single-center experience. Ann Surg Oncol 22:S1212-S1220,2015.
- 11) Gemenetzis G, Groot VP, Blair AB, et al.:Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg 270:340-347,2019.
- 12) Kunzmann V, Ramanathan RK, Goldstein D, et al.:Tumor reduction in primary and metastatic pancre-atic cancer lesions with nab-paclitaxel and gem-citabine:an exploratory analysis from a phase 3 study. Pancreas 46:203-208,2017.
- 13) Philip PA, Lacy J, Portales F, et al.:Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer(LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol 5:285-294,2020.
- 14) Schneitler S, Kropil P, Riemer J, et al.:Metastasized pancreatic carcinoma with neoadjuvant FOLFIRI-NOX therapy and R0 resection. World J Gastroen-terol 21:6384-6390,2015.
- 15) Frigerio I, Regi P, Giardino A, et al.:Downstaging in stage IV pancreatic cancer: a new population eligible for surgery? Ann Surg Oncol 24:2397-2403,2017.
- 16) National Comprehensive Cancer Network(R):NCCN Clinical Practice Guidelines for Pancreatic Adenocar-cinoma, Version 1. 2020(https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf).
- 17) Le DT, Durham JN, Smith KN, et al.:Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409-413,2017.
- 18) Eso Y, Shimizu T, Takeda H, et al.:Microsatellite instability and immune checkpoint inhibitors:toward precision medicine against gastrointestinal and hepa-tobiliary cancers. J Gastroenterol 55:15-26,2020.
- 19) Marabelle A, Le DT, Ascierto PA, et al.:Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer:results from the phase II KEYNOTE-158 study. J Clin Oncol 38:1-10,2020.
- 20) Doebele RC, Drilon A, Paz-Ares L, et al.:Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours:integrated analysis of three phase 1-2 trials. Lancet Oncol 21:271-282,2020.
